A review of therapeutic agents for the management of pulmonary arterial hypertension. (January 2017)

• Record Type: Journal Article
• Authors: Hahn, Stella S; Makaryus, Mina; Talwar, Arunabh; Narasimhan, Mangala; Zaidi, Gulrukh
• Is Part Of: Therapeutic advances in respiratory disease. Volume 11:Number 1(2017)
• Page Start: 46
• Page End: 63
• Publication Date: 2017-01
• Subjects: pulmonary arterial hypertension -- prostanoid -- endothelin receptor antagonist -- phosphodiesterase inhibitor -- soluble guanylate cyclase stimulator; Respiratory organs -- Diseases -- Periodicals; Respiratory agents -- Periodicals; Pulmonary pharmacology -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System Agents -- therapeutic use -- Periodicals; Respiratory Tract Diseases -- drug therapy -- Periodicals; Lung Diseases -- drug therapy -- Periodicals; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Agents respiratoires -- Périodiques; Pharmacologie pulmonaire -- Périodiques; 616.2005
• DOI: 10.1177/1753465816665289
• Languages: English
• ISSNs: 1753-4658

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon, progressive and life threatening disease characterized by a proliferative vasculopathy of the small muscular pulmonary arterioles resulting in elevated pulmonary vascular resistance and eventually right ventricular failure. An increasing understanding of the pathobiology of PAH and its natural history has led to the development of numerous targeted therapies. Despite these advances there is significant progression of disease and the survival rate remains low. This article reviews the agents currently available for the medical management of PAH.